Compare Gilead Sciences, Inc. (GILD) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Occidental Petroleum Corporation — how do they compare? Gilead Sciences, Inc. trades at $135.88 (market cap $163.51B), while Occidental Petroleum Corporation trades at $53.65 (market cap $53.48B). The key difference: Gilead Sciences, Inc. is far larger — about 3.1× Occidental Petroleum Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | OXY | |
|---|---|---|
Market Cap | $163.51B | $53.48B |
Sector | Health | Energy |
52-Week High | $155.80 | $66.24 |
52-Week Low | $108.22 | $38.92 |
Enterprise Value | $178.05B | $74.57B |
Dividend Yield | 2.49% | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Occidental Petroleum (OXY) trades at $54.02, down 1.01% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 5. Recent news highlights improved capital efficiency and debt reduction, while analyst consensus shows 50% buy ratings with a $66.14 price target. Revenue has declined from $36.6B in 2022 to $21.6B in 2025, though net margins remain healthy at 10.77%.
OXY presents a mixed outlook with strong operational performance and analyst optimism offset by declining revenue trends. The stock offers potential upside to consensus targets but faces risks from oil price volatility and execution challenges under new leadership. Key catalysts include Q2 earnings and continued progress on debt reduction initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
